Chest Mobility, Cough Strength, Muscle Strength, Physical Activity and Quality of Life in Parkinson’s Patients with post-COVID-19

Not Applicable

• Conditions: Decreased Chest Mobility; Physical inactivity; Weakness in Cough Strength; Infection - Other infectious diseases; Weakness in Muscle Strength; Poor Quality of Life; Parkinsonism; COVID-19; Neurological - Parkinson's disease

• Registration Number: ACTRN12623000564651
• Lead Sponsor: GÜLSAH BARGI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-25
• Last Update Posted: 5 June 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Inclusion criteria for Parkinson's patients with COVID-19;
• Being diagnosed with COVID-19 at least 12 weeks ago and recovered,
• Being over 18 years old,
• Volunteering to participate in the research,
• Being diagnosed with Parkinson's disease
• Comorbid conditions (such as hypertension, diabetes) are under control
• Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
• Having the ability to ambulate and walk independently
• Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Inclusion criteria for Parkinson's patients without COVID-19;
• Not being diagnosed or suspected of COVID-19
• Being over 18 years old,
• Volunteering to participate in the research,
• Being diagnosed with Parkinson's disease
• Having comorbid conditions (such as hypertension, diabetes) which are under control
• Being able to perceive assessments (Standardized Mini Mental Test score of 24 and above)
• Having the ability to ambulate and walk independently
• Being in stage 1 - 4 according to the Modified Hoehn-Yahr Scale

Exclusion Criteria

Exclusion criteria for Parkinson's patients with and without COVID-19;
• Sudden drug or dose change during the study period
• A history of any acute/chronic orthopedic, cardiovascular, pulmonary, psychiatric or neuromuscular disease that may prevent measurements from being made.
• Having had myocardial infarction and pulmonary embolism in the last 30 days,
• Having a history of additional neurological (stroke, head trauma, peripheral nerve diseases, brain and spinal cord tumors, etc.) diseases other than Parkinson's disease
• Having severe vision loss or vestibular dysfunction
• Patients with blood pressure values above 140/90 and below 90/50 in blood pressure measurements made before the study, with arrhythmia on ECG, with a history of shortness of breath and/or palpitation

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The status of quality of life will be evaluated using Parkinson’s Disease Questionnaire (PDQ-39) questionnaire.[at survey time]

Secondary Outcome Measures

Name	Time	Method
Cough Strength will be evaluated using a Peak Flow Meter<br>[at survey time];Daily average step counts will be recorded via a pedometer. All individuals will be asked to carry their pedometers with them during the day and record to their diaries.[at survey time, everyday within 3 days after confirming enrolment];Hand grip strength will be evaluated using a hand dynamometer.[at survey time];Chest mobility will be evaluated using a tape measure.[at survey time];<br>Cognitive state will be evaluated using The mini–mental state examination (MMSE)[at survey time]